In 2012:
- Seymour was touting all the drugs he was soon to get into the clinic, and all the partners on the horizon.
- The company had can accumulated deficit of a fraction of where it is today.
- The company was four years younger,
- The company was "successfully raising funds".
In 2016:
- Seymour has a few lame schedules that are all expired.
- The company hasn't even identified a candidate to take into the clinic. The company is still years away from getting to where they said they'd be years ago.
- The company is moving into it's twelfth year of failing to get a single candidate IND-approved.
- In contrast to 2012, the company is NOT successfully raising funds at present, and has no prospective partners to tout.
The company will have a much harder time finding funding today than it did in 2012. If it can find funding, it will come at a much higher cost, and be highly dilutive. It will likely involve selling shares at a sufficient discount to the current market price to guarantee buyers a quick and healthy profit when they dump, and they will dump.
Those are the facts.